Mary Lynne Hedley

This inventor holds 13 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Harvard College, Mgi Pharma Biologics, Inc., Zycos Inc.. Active years: 1998-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mary Lynne Hedley. Retrieved from https://idiyas.com/inventor/mary-lynne-hedley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 7)

% Patents Active = 84.6

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 4.0

ph-index = 7

Forward Citations = 282(Granted Patents)

Location History:

Somerville, MA (US) (1998 - 2003)
Lexington, MA (US) (2000 - 2012)

Company Filing History:

Mgi Pharma Biologics, Inc.

Years Active: 1998-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12527780 - Methods of treating ovarian cancer (2026-01-20),

2. 12383542 - Methods of treating ovarian cancer (2025-08-12),

3. 8158594 - CYP1B1 nucleic acids and methods of use (2012-04-17),

4. 7241742 - CYP1B1 nucleic acids and methods of use (2007-07-10),

5. 7169603 - α-MSH related compounds and methods of use (2007-01-30),

6. 7097843 - Immunogenic peptides from the HPV E7 protein (2006-08-29),

7. 6696061 - Immunomodulatory peptides (2004-02-24),

8. 6582704 - Immunogenic peptides from the HPV E7 protein (2003-06-24),

9. 6509033 - Immunomodulatory peptides (2003-01-21),

10. 6183746 - Immunogenic peptides from the HPV E7 protein (2001-02-06),

11. 6013258 - Immunogenic peptides from the HPV E7 protein (2000-01-11),

12. 5880103 - Immunomodulatory peptides (1999-03-09),

13. 5827516 - Immunomodulatory peptides (1998-10-27),

Title: Mary Lynne Hedley: Innovator in Cancer Treatment

Introduction

Mary Lynne Hedley is a prominent inventor based in Lexington, MA (US). She has made significant contributions to the field of cancer treatment, holding a total of 13 patents. Her work focuses on innovative methods that aim to improve patient outcomes in oncology.

Latest Patents

Among her latest patents, one notable invention is related to methods of treating ovarian cancer. This invention provides methods of administering a PARP inhibitor to a cancer patient, showcasing her commitment to advancing cancer therapies. Another significant patent involves CYP1B1 nucleic acids and methods of use. This invention offers nucleic acids containing transcriptional units that encode CYP1B1 polypeptides, which lack sequences found in the untranslated region of naturally occurring forms of the CYP1B1 transcript. The invention enhances the translation of the CYP1B1 polypeptide, providing a promising avenue for treating proliferative disorders or cancer.

Career Highlights

Mary Lynne Hedley has worked with esteemed organizations such as Harvard College and MGI Pharma Biologics, Inc. Her experience in these institutions has allowed her to develop and refine her innovative ideas in the field of biotechnology and cancer research.

Collaborations

Throughout her career, Mary has collaborated with notable individuals, including Roman M. Chicz and Robert G. Urban. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Mary Lynne Hedley is a trailblazer in the field of cancer treatment, with a strong portfolio of patents that reflect her dedication to improving patient care. Her innovative approaches continue to inspire advancements in oncology.

Profile summary based on public USPTO records.